Last edition
News about "Nivolumab biosimilar"
Dr. Reddy's launches NIVORZ in India
Dr. Reddy’s has launched NIVORZ, a nivolumab biosimilar in India, marking its entry into biosimilar immuno-oncology with approval across 12 cancer indications.
Nivolumab Biosimilar | 16/09/2026 | By News Bureau
Zydus Launches World's First Nivolumab Biosimilar 'Tishtha' in India
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the immunotherapy drug nivolumab, in India, aimed at expanding access to advanced cancer care by offering the treatment at nearly one-fourth the cost of the reference product for patients with multiple cancer types.
Nivolumab Biosimilar | 23/01/2026 | By News Bureau | 1162
Zydus Challenges Delhi HC Order Blocking Sale of Cancer Drug Biosimilar
The single-judge order, issued on July 18, 2025, prohibits Zydus from manufacturing, selling, advertising, importing, or exporting its Nivolumab biosimilar until the final outcome of the case or the expiry of the suit patent on May 2, 2026.
Nivolumab Biosimilar | 25/07/2025 | By Darshana | 708
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy